NCT04752696Phase 2Terminated

Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma

Study sponsor: Cardiff Oncology

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-12-24Actual
Enrollment · participants41Actual
Source updated2026-11-04Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Overall Response Rate (ORR) Time frame: Up to 2 years. After: Measure: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Description: ORR was defined as the percentage of participants who achieved a best overall response of confirmed complete reponse (CR) or partial response (PR) determined by the Investigator per RECIST v1.1. According to RECIST 1.1, a CR is the disappearance of all target lesions, with non-target lesions non-existent and no new lesions and a PR is a decrease of at least 30% in the sum of the diameters of target lesions, as long as there are no new lesions and non-target lesions have not worsened. Two-sided 95% confidence interval (CI) was calculated using the exact binomial Clopper-Pearson method. Time frame: Up to approximately 91 weeks.

Recruitment status changed

Before: Completed. After: Terminated.

Check registry source

· 1 field changed

Actual enrollment decreased by 2 participants

Before: 43 participants (actual). After: 41 participants (actual).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview